NASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $320.56 -3.80 (-1.17%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$319.00▼$326.9750-Day Range$309.38▼$335.9752-Week Range$249.70▼$346.85Volume2.24 million shsAverage Volume2.54 million shsMarket Capitalization$171.96 billionP/E Ratio45.79Dividend Yield2.81%Price Target$327.28 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Amgen alerts: Email Address Amgen MarketRank™ Stock AnalysisAnalyst RatingHold2.48 Rating ScoreUpside/Downside2.1% Upside$327.28 Price TargetShort InterestHealthy1.72% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainability-2.42Upright™ Environmental ScoreNews Sentiment0.76Based on 19 Articles This WeekInsider TradingN/AProj. Earnings Growth5.28%From $19.49 to $20.52 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.47 out of 5 starsMedical Sector94th out of 910 stocksBiological Products, Except Diagnostic Industry9th out of 155 stocks 2.2 Analyst's Opinion Consensus RatingAmgen has received a consensus rating of Hold. The company's average rating score is 2.48, and is based on 10 buy ratings, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageAmgen has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.72% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Amgen has recently decreased by 5.62%, indicating that investor sentiment is improving significantly. Previous Next 3.3 Dividend Strength Dividend YieldAmgen pays a meaningful dividend of 2.72%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 13 years.Dividend CoverageThe dividend payout ratio of Amgen is 128.57%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 43.86% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmgen has received a 53.36% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Denosumab", "Etanercept", "Darbepoetin alfa", and "Apremilast" products. See details.Environmental SustainabilityThe Environmental Impact score for Amgen is -2.42. Previous Next 2.1 News and Social Media Coverage News SentimentAmgen has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Amgen this week, compared to 20 articles on an average week.Search InterestOnly 36 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.MarketBeat FollowsOnly 18 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is a decrease of -28% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.69% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Amgen are expected to grow by 5.28% in the coming year, from $19.49 to $20.52 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 45.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 45.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.16.Price to Earnings Growth RatioAmgen has a PEG Ratio of 2.96. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 29.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amgen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press Fmr CIA Advisor reveals PEACEMAKER superweaponKamala cannot get the “codes” to this superweapon. In Trump’s hands, it will restore America’s global dominance. It could also help Americans struggling under Bidenomics by potentially sending 5 military stocks SOARING. Historically, similar stocks have shot up 16,270% in just 18 months.Full details are in this announcement. About Amgen Stock (NASDAQ:AMGN)Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.Written by Jeffrey Neal JohnsonRead More AMGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMGN Stock News HeadlinesAugust 27, 2024 | marketbeat.comBoogers, Biotech and Health Insurance: The Safest Dividends for a RecessionLet’s talk about recession-resistant dividends because, if history is any guide, we are certainly “on the clock” for a slowdown if not already in one.August 26, 2024 | marketbeat.comEli Lilly’s Path to the Next Trillion Market Capitalization (AMGN)Eli Lilly and Co. (NYSE: LLY) is a pharmaceutical giant that's made headlines for its GLP-1/GIP weight loss drug Tirzepatide, aka Mounjaro, for Type 2 diabetes.September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 10, 2024 | marketbeat.comMarketBeat Week in Review – 8/5 - 8/9 (AMGN)Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earningsAugust 9, 2024 | marketbeat.comAmgen's MariTide Weight Loss Potential: Stock Outlook (AMGN)Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.September 6 at 2:17 AM | americanbankingnews.comAmgen Inc. (NASDAQ:AMGN) Receives $326.89 Average Price Target from BrokeragesSeptember 5 at 4:51 PM | seekingalpha.comAmgen Inc. (AMGN) Wells Fargo 2024 Healthcare Conference (Transcript)September 4 at 1:17 PM | seekingalpha.comAmgen Inc. (AMGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.September 4 at 10:08 AM | reuters.comAmgen to test its obesity drug in patients at risk of obesity-related diseasesSeptember 3, 2024 | marketwatch.comAmgen Inc. stock underperforms Tuesday when compared to competitorsSeptember 3, 2024 | finance.yahoo.comAmgen Insiders Sell US$4.0m Of Stock, Possibly Signalling CautionSeptember 3, 2024 | americanbankingnews.comAmgen Inc. (NASDAQ:AMGN) Sees Significant Decrease in Short InterestSeptember 3, 2024 | barrons.comNovo, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them SoaringAugust 31, 2024 | americanbankingnews.comZacks Research Analysts Raise Earnings Estimates for Amgen Inc. (NASDAQ:AMGN)August 30, 2024 | prnewswire.comAMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCEAugust 30, 2024 | benzinga.comAmgen Unusual Options Activity For August 29August 29, 2024 | prnewswire.comAMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCESee More Headlines Receive AMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Dividend Payable8/06/2024Ex-Dividend for 8/6 Dividend8/16/2024Today9/07/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CUSIP03116210 CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees26,700Year Founded1980Price Target and Rating Average Stock Price Target$327.28 High Stock Price Target$381.00 Low Stock Price Target$235.00 Potential Upside/Downside+2.1%Consensus RatingHold Rating Score (0-4)2.48 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$7.00 Trailing P/E Ratio45.79 Forward P/E Ratio16.45 P/E Growth2.96Net Income$6.72 billion Net Margins10.12% Pretax Margin11.40% Return on Equity161.72% Return on Assets10.81% Debt Debt-to-Equity Ratio9.64 Current Ratio1.26 Quick Ratio0.89 Sales & Book Value Annual Sales$30.93 billion Price / Sales5.56 Cash Flow$25.30 per share Price / Cash Flow12.67 Book Value$11.03 per share Price / Book29.06Miscellaneous Outstanding Shares536,435,000Free Float532,734,000Market Cap$171.96 billion OptionableOptionable Beta0.58 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Robert A. Bradway (Age 61)Chairman, CEO & President Comp: $6.73MMr. Peter H. Griffith (Age 65)Executive VP & CFO Comp: $3.07MMr. Esteban Santos (Age 56)Executive Vice President of Operations Comp: $3.01MDr. David M. Reese M.D. (Age 61)Executive VP & Chief Technology Officer Comp: $3.4MMr. Murdo Gordon (Age 57)Executive Vice President of Global Commercial Operations Comp: $3.24MMr. Matthew C. Busch (Age 50)Chief Accounting Officer & VP of Finance Mr. Mike ZahigianSenior VP & Chief Information OfficerDr. James E. Bradner M.D. (Age 52)Executive VP of Research and Development & Chief Scientific Officer Justin G. ClaeysVice President of Investor RelationsMr. Jonathan P. Graham (Age 63)Executive VP, General Counsel & Secretary Comp: $2.44MMore ExecutivesKey CompetitorsRegeneron PharmaceuticalsNASDAQ:REGNVertex PharmaceuticalsNASDAQ:VRTXGilead SciencesNASDAQ:GILDSeagenNASDAQ:SGENAlnylam PharmaceuticalsNASDAQ:ALNYView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 67,369 shares on 9/5/2024Ownership: 0.013%Brown Financial AdvisorsBought 2,417 shares on 8/30/2024Ownership: 0.000%Souders Financial AdvisorsBought 11,376 shares on 8/28/2024Ownership: 0.003%Heritage Oak Wealth Advisors LLCBought 1,872 shares on 8/28/2024Ownership: 0.000%Dana Investment Advisors Inc.Sold 40 shares on 8/27/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy Amgen Stock? AMGN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Amgen Inc.: Amgen's stock price has been steadily increasing, reaching $331.01 on the latest trading day, indicating positive momentum. Amgen has a strong track record of dividend payments, offering investors a steady income stream. Recent analyst ratings have been positive, with several analysts upgrading the stock to a "buy" rating, indicating confidence in the company's future performance. Amgen's revenue for the latest quarter exceeded analyst estimates, showing strong financial performance. Amgen's diverse portfolio of human therapeutics positions the company well for growth and innovation in the healthcare sector. Cons Investors should be bearish about investing in Amgen Inc. for these reasons: Amgen's debt-to-equity ratio is high at 11.96, indicating a significant level of debt that may pose risks in the future. Amgen's price-to-earnings ratio of 47.29 is relatively high, suggesting the stock may be overvalued compared to industry peers. Despite positive analyst ratings, there is always a level of uncertainty in the biopharmaceutical industry due to regulatory challenges and competition. Amgen's beta of 0.58 indicates lower volatility compared to the market, potentially limiting short-term trading opportunities for investors seeking high returns. Investors should consider the potential impact of macroeconomic factors on Amgen's business, such as healthcare policy changes or global economic conditions. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 3, 2024. Please send any questions or comments about these Amgen pros and cons to contact@marketbeat.com. AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $288.02 on January 1st, 2024. Since then, AMGN shares have increased by 11.3% and is now trading at $320.56. View the best growth stocks for 2024 here. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings data on Tuesday, August, 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by $0.04. The firm's quarterly revenue was up 20.1% on a year-over-year basis. Read the conference call transcript. What is Robert A. Bradway's approval rating as Amgen's CEO? 1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend. Does Amgen have any subsidiaries? Amgen subsidiaries include these companies: TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more. Who are Amgen's major shareholders? Amgen's top institutional investors include Primecap Management Co. CA (2.69%), Bank of New York Mellon Corp (1.00%), Legal & General Group Plc (0.90%) and Dimensional Fund Advisors LP (0.50%). Insiders that own company stock include Amgen Inc, Murdo Gordon, Jonathan P Graham, Robert Eckert, Nancy A Grygiel, Nancy A Grygiel and R Sanders Williams. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV) and Walt Disney (DIS). This page (NASDAQ:AMGN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMGN Stock Alerts